There are 594 resources available
32P - The impact of renal dysfunction and pemetrexed administration dose in KEYNOTE189 on prognosis
Presenter: Yuta Yamanaka
Session: Poster Display session
33P - A multi-country time & motion (T&M) study of subcutaneous (SC) vs intravenous (IV) pembrolizumab (Pembro) plus chemotherapy (Chemo) in metastatic non-small cell lung cancer (mNSCLC)
Presenter: Erwin De Cock
Session: Poster Display session
34P - Polymeric micelles paclitaxel (pm-Pac), carboplatin combined with sintilimab in the first-line treatment of advanced non-squamous non-small cell lung cancer(nsq-NSCLC): Phase II study
Presenter: Yun Zhou
Session: Poster Display session
35P - Clinical and safety outcomes of cancer vaccines in patients with advanced non-small cell lung cancer after first-line therapy: A systematic review and meta-analysis
Presenter: Shaoyi Chen
Session: Poster Display session
36P - Efficacy and safety of datopotamab deruxtecan on advanced/metastatic non-small cell lung cancer patients: A systematic review and single-arm meta-analysis
Presenter: Henrique Kim
Session: Poster Display session
37P - Tislelizumab (TIS) combined with chemotherapy (CT) as first-line (1L) therapy for locally advanced or metastatic nonsquamous non-small cell lung cancer (LA/M nsq-NSCLC): Programmed death-ligand 1 (PD-L1) expression ≥50% subgroup analysis of the randomized, phase III RATIONALE-304 trial
Presenter: Yan Yu
Session: Poster Display session
38P - Two years of follow-up data of a phase II clinical trial of atezolizumab with bevacizumab for patients with PD-L1 high expression non-squamous non-small cell lung cancer (WJOG10718L/@ Be Study)
Presenter: Takashi Seto
Session: Poster Display session
39P - Real-world efficacy and safety of anlotinib in NSCLC previously treated with immune checkpoint inhibitors
Presenter: Yuchao Dong
Session: Poster Display session
40P - Metformin plus/minus cyclic fasting mimicking diet to improve the efficacy of first-line chemo-immunotherapy in advanced LKB1-inactive NSCLC: Results of the phase II trial FAME
Presenter: Mario Occhipinti
Session: Poster Display session
41P - Network meta-analysis (NMA) of the first-line therapy for advanced non-squamous non-small cell lung cancer (nsNSCLC): Does PD-L1 expression modify effect of the immunotherapy on the overall survival (OS)?
Presenter: Mikhail Fedyanin
Session: Poster Display session